Skip to main content
Equibles
LENZ logo

LENZ · LENZ Therapeutics, Inc. · Metrics

Track LENZ — free

Use LENZ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LENZ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.84 +0.34 (+9.85%) Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$109.97M
Shares
31.42M
Volume · Nov 9 202.63K Avg daily vol (3M) 879.3K

LENZ metrics

85 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.50
Market cap
$109.97M

Price action

23 metrics
Price change (1W)
+14.8%
Price change (30D)
-4.0%
Price change (3M)
-34.7%
Price change (6M)
-65.2%
Price change (YTD)
-78.1%
Price change (1Y)
-84.8%
Trailing year
Price change (5Y)
—
52-week high
$31.94
52-week low
$3.01
Change from 52-week high
-89.0%
Change from 52-week low
+16.3%
Annualized volatility
81.3%
Annualized volatility (3M)
84.5%
Implied volatility (30D)
103.5%
IV rank (1Y)
28.5
IV percentile (1Y)
64.1
Beta
1.8
RSI (14D)
50.6
Price vs SMA 50
-10.9%
Price vs SMA 200
-54.1%
Avg volume (3M)
879,302
Relative volume
0.9
Average dollar volume
$3.52M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
31.42M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
6.4×
reciprocal yield 15.6%
EV / EBITDA
—
EV / EBIT
—
P / sales
8.9×
reciprocal yield 11.2%
P / book
0.6
reciprocal yield 174.6%
FCF yield
-116.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-127.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
2024-03-22

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-29

Profitability

9 metrics
Gross margin
82.0%
Operating margin
-1,211.2%
Trailing 12 months
Net margin
-1,135.0%
Gross profit (TTM)
$10.13M
Operating profit (TTM)
−$149.69M
Net income (TTM)
−$140.27M
Trailing 12 months
Diluted EPS (TTM)
$-4.53
FCF margin
-1,033.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.39
Gross profit per diluted share (TTM)
$0.32
Operating profit per diluted share (TTM)
$-4.78
EBITDA per diluted share (TTM)
$-4.77
Net income per diluted share (TTM)
$-4.48
Operating cash flow per diluted share (TTM)
$-4.08
Free cash flow per diluted share (TTM)
$-4.08
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.00
Stock compensation per diluted share (TTM)
$0.53
Book value per share
$9.07

Growth

11 metrics
Revenue growth YoY
-72.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$12.36M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+10.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-73.1%
Return on assets
-66.9%
Debt / equity
0.0
Current ratio
11.7
EBITDA (TTM)
−$149.25M
Free cash flow (TTM)
−$127.70M
Quick ratio
11.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$30.55M
Latest balance sheet
Cash & equivalents
$30.55M
Total assets
$209.75M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$127.63M
Capital expenditures (TTM)
$72,000
R&D (TTM)
$0
SG&A (TTM)
$159.82M
Stock compensation (TTM)
$16.60M
R&D / revenue
0.0%
Stock compensation / revenue
134.3%

Ownership (13F)

9 metrics
13F filers
147
13F filer change QoQ
-1
Institutional ownership
111.6%
Conviction holders (share of 13F filers)
2.1%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.0%
Holder tenure
6.8
Price vs estimated holder cost
-72.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
9.8%

Short interest

3 metrics
Short interest
28.9%
Latest settlement · 11.8 days to cover
Days to cover
11.8d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1815776 CUSIP 52635N103 13F (30d) 47 filings 43 filers Visit website Investor relations